ID   MOLM-13-RES-AC
AC   CVCL_D780
DR   Cosmic; 1741691
DR   Wikidata; Q54906322
RX   PubMed=22354205;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:90217; Quizartinib (AC220).
CC   Selected for resistance to: ChEBI; CHEBI:90237; Tandutinib (MLN518; CT53518).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   NCIt; C3247; Myelodysplastic syndrome
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D779 ! MOLM-13-RES
SX   Male
AG   20Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 15
//
RX   PubMed=22354205; DOI=10.1038/leu.2012.52;
RA   Moore A.S., Faisal A., Gonzalez de Castro D., Bavetsias V., Sun C.-B.,
RA   Atrash B., Valenti M., De Haven Brandon A.K., Avery S., Mair D.,
RA   Mirabella F., Swansbury J., Pearson A.D.J., Workman P., Blagg J.,
RA   Raynaud F.I., Eccles S.A., Linardopoulos S.;
RT   "Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia
RT   resulting in secondary D835Y mutation: a model for emerging clinical
RT   resistance patterns.";
RL   Leukemia 26:1462-1470(2012).
//